Prognostic validity of the American joint committee on cancer eighth edition staging system for well-differentiated pancreatic neuroendocrine tumors

BackgroundThe American Joint Committee on Cancer (AJCC) made improvements for staging pancreatic neuroendocrine tumors (pNETs) in its 8th Edition; however, multicenter studies were not included.MethodsWe collected multicenter datasets (n = 1,086, between 2004 and 2018) to validate the value of AJCC 8 and other coexisting staging systems through univariate and multivariate analysis for well-differentiated (G1/G2) pNETs.ResultsCompared to other coexisting staging systems, AJCC 7 only included 12 (1.1%) patients with stage III tumors. Patients with European Neuroendocrine Tumor Society (ENETS) stage IIB disease had a higher risk of death than patients with stage IIIA (hazard ratio [HR]: 4.376 vs. 4.322). For the modified ENETS staging system, patients with stage IIB disease had a higher risk of death than patients with stage III (HR: 6.078 vs. 5.341). According to AJCC 8, the proportions of patients with stage I, II, III, and IV were 25.7%, 40.3%, 23.6%, and 10.4%, respectively. As the stage advanced, the median survival time decreased (NA, 144.7, 100.8, 72.0 months, respectively), and the risk of death increased (HR: II = 3.145, III = 5.925, and IV = 8.762).ConclusionThese findings suggest that AJCC 8 had a more reasonable proportional distribution and the risk of death was better correlated with disease stage.     

Replantation and Lengthening of a Lower Leg in a 7-Year-Old Child: A Case Report

Replantation of the lower leg has controversial indications, but it may be considered in carefully selected patients. Although the function of prosthetic lower legs has been improved in recent decades, leg salvage remains a laudable goal. We present the case of a 7-year-old child who sustained a traumatic amputation at the level of the middle tibia with loss of the middle portion of the lower leg. We performed successful replantation, and tibia lengthening was performed starting 10 days after replantation and lasted 6 months.     

转录调节因子c-Myb通过炎症因子Ccl2抑制乳腺癌肺转移的实验研究

目的:研究乳腺癌细胞中转录调节因子c-Myb的表达对肺转移的影响及其分子机制。方法:构建c-Myb高表达的4T1乳腺癌细胞株，种植小鼠构建乳腺癌动物模型，检测实验动物肺转移情况，通过荷瘤抑制试验检测肺转移抑制效果。提取组织进行荧光PCR检测相关炎症因子的表达。利用Medisapiens数据库的生物信息学资源，对c-Myb和Ccl2的表达与乳腺癌患者的预后进行分析。结果:高表达c-Myb的荷瘤小鼠肺部转移灶明显减少，其中炎症相关因子表达受限。由数据库分析得出，c-Myb高表达患者生存期得以延长。结论:乳腺癌中c-Myb的表达能够通过炎症因子Ccl2抑制肺转移从而延长患者生存期。     

顶空气相色谱-质谱法测定布南色林原料药中遗传毒性杂质

目的：建立顶空气相色谱-质谱法测定布南色林原料药中甲磺酸甲酯、甲磺酸乙酯和甲磺酸异丙酯3种遗传毒性杂质含量的方法。方法：采用顶空气相色谱-质谱法，以甲磺酸丁酯为内标，按内标标准曲线法进行甲磺酸甲酯、甲磺酸乙酯和甲磺酸异丙酯的含量测定。色谱条件：DB-WAX毛细管色谱柱（30 m×0.25 mm×0.25 μm）；程序升温，初始柱温为40℃，维持3 min，升温速率为30℃·min^-1，终止温度150℃，保持2 min；进样口温度为110℃；载气（He）流速为0.6 mL·min^-1；进样量为1 mL；进样方式为分流进样，分流比为20：1。质谱条件：电子轰击离子源（EI），扫描方式为选择性离子检测；离子源温度为200℃；接口温度为150℃；电子能量为70 eV；溶剂延迟1 min。结果：3种杂质成分之间的分离度均大于2.0；甲磺酸甲酯、甲磺酸乙酯、甲磺酸异丙酯检测质量浓度线性范围均为0.025~3.0 μg·mL^-1（r ≥ 0.998 5）；精密度、稳定性、重复性试验的RSD<5%；加样回收率分别为93.40%~101.40%（RSD为3.2%，n=9）、92.80%~99.70%（RSD为2.5%，n=9）和96.30%~100.75%（RSD为1.6%，n=9）。结论：该方法简便、准确、灵敏、迅速，可用于布南色林原料药中3种遗传毒性杂质的测定。     

外固定架治疗桡骨远端粉碎性骨折的疗效分析

目的:探讨闭合手法复位外固定架治疗桡骨远端粉碎性关节内骨折的临床疗效。方法:对29例桡骨远端粉碎性关节内骨折,通过外固定架的牵伸辅助复位,矫正桡骨的短缩、成角移位,恢复关节面的解剖关系,利用外固定架维持复位后的位置并进行功能练习。术后定期进行X线和腕关节功能的评价。结果:29例均获得随访,随访时间3~12个月,平均6.5个月。根据Aro功能评价:优9例,良17例,可2例,差1例,优良率89.66%。结论:外固定架能很好维持复位后的位置,恢复桡尺骨的相对长度和关节面的平整,使腕关节功能得到良好的恢复,因此是治疗桡骨远端粉碎性关节内骨折的有效方法。     

经肝动脉As2O3碘化油化疗栓塞 对兔肝移植瘤生长及转移的影响

目的观察As2O3与碘油联合经肝动脉化疗栓塞术后对兔VX2肝移植瘤生长及转移的作用.方法 40只家兔肝内肿瘤种植后2周,随机分为5组,经肝动脉插管分别给予不同处理,实验设生理盐水灌注组、As2O3灌注组、单纯碘油栓塞组、阿霉素碘油栓塞及As2O3碘油栓塞组,As2O3的用量为2 mg/kg.肿瘤种植后5周,测量动物体重,所有动物均处死,取出肝脏及双肺标本,测定肝脏的重量,计算肝移植瘤的体积、坏死面积,观察肝内、双肺及其他器官肿瘤转移的发生率.结果肿瘤植入后5周,各处理组动物体重均有明显的下降,肝脏重量增加,计算的肝指数各组分别为9.8±2.2、9.7±2.1、8.5±2.0、8.4±2.1、6.4±1.2;肿瘤体积分别为(35.5±7.6) cm3、(32.2±9.7) cm3、(21.2±8.5) cm3、(20.9±11.3) cm3、(11.8±4.0) cm3,栓塞治疗组与非栓塞治疗组间差异有统计学意义,As2O3碘油栓塞治疗组与其他组相比差异有统计学意义.平均坏死率各组间差异无明显的统计学意义.双肺转移结节的数目各组分别为52.4±32.2、51.8±26.3、54.8±29.2、53.5±30.7、19.6±17.0;转移结节的直径各组分别为(3.8±1.2) mm、(3.6±1.1) mm、(3.9±1.3) mm、(3.5±1.6) mm、(2.2±0.7) mm.As2O3碘油栓塞治疗组与其他各组相比差异有统计学意义(P<0.05).结论 As2O3与碘油联合经肝动脉栓塞治疗,可抑制肝移植瘤的生长及肺转移.     

Correlation between Cyclin A Gene Expression in Adult Patients with Acute Leukemia and Drug Resistance

Adultacuteleukemia (AL)isoneofthemostcommonmalignanttumorsofhematology .Withtherecentprogressinchemotherapyandsupportivether apy ,theremissionandsurvivalrateinALhavebeenmarkedlyimproved .However ,drugresistanceandrelapsearestillimportantfactorsaffectinglongsur vivalofthese patients .Theabnormalregulationofcellcycleisanotherfactorthatcannotbeignoredex ceptformultipledrugresistance (MDR) .WedetectcyclinA ,multidrugresistantgene (mdrl) ,topoiso meraseⅡα(TopⅡα)andbcl 2inadultpatientswithA…